STERIS (STE) Stock Forecast & Price Target

$218.20 -0.66 (-0.30%)

(As of 12:30 PM ET)

STERIS - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
2

Buy
4

Based on 6 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 2 have given a hold rating, and 4 have given a buy rating for STE.

Consensus Price Target

$253.00
15.95% Upside

According to the 6 analysts' twelve-month price targets for STERIS, the average price target is $253.00. The highest price target for STE is $265.00, while the lowest price target for STE is $215.00. The average price target represents a forecasted upside of 15.95% from the current price of $218.20.

Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

STE Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$253.00	$253.00	$246.00	$240.60
Forecasted Upside	15.95% Upside	12.35% Upside	2.33% Upside	20.74% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

STERIS Stock vs. The Competition

Type	STERIS	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.59% Upside	25,883.65% Upside	6.71% Upside
News Sentiment Rating	Positive News See Recent STE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/18/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$265.00 ➝ $265.00	+20.53%
11/8/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Hold
11/7/2024	Stephens 4 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$260.00 ➝ $260.00	+21.88%
10/24/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Bednar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$230.00 ➝ $260.00	+17.57%
9/3/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$255.00 ➝ $265.00	+9.11%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$225.00 ➝ $215.00	+5.65%
Get the Latest News and Ratings for STE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:50 PM ET.

Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 1, 2024. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

Here are some ways that investors could benefit from investing in STERIS plc:

STERIS plc reported earnings per share (EPS) of $2.14 for the latest quarter, exceeding the consensus estimate of $2.12, indicating strong financial performance and effective management.
The company has shown a year-over-year revenue growth of 7.3%, reaching $1.33 billion, which reflects its ability to expand and capture market share in the medical equipment sector.
STERIS plc has declared a quarterly dividend of $0.57, with a dividend yield of 1.08%. This consistent dividend payment can provide a steady income stream for investors.
Analysts have set a consensus price target of $253.00 for STERIS plc, with several firms issuing buy ratings, suggesting potential for stock price appreciation.
The company maintains a return on equity of 13.78%, which indicates efficient use of shareholders' equity to generate profits, a positive sign for investors looking for solid returns.

STERIS
Bear Case

Investors should be bearish about investing in STERIS plc for these reasons:

Insider selling has been observed, with the CFO selling 23,332 shares, which may raise concerns about the company's future prospects and insider confidence.
The stock has experienced fluctuations, with recent price targets ranging from $260.00 to $265.00, indicating uncertainty in market sentiment.
Despite the positive revenue growth, the net margin stands at 8.02%, which may suggest that the company faces challenges in controlling costs and maximizing profitability.
With a dividend payout ratio of 52.05%, there is a risk that future dividends could be reduced if the company faces financial difficulties or if it needs to reinvest profits for growth.
Market analysts have mixed ratings, with some firms maintaining a hold rating, which may indicate a lack of strong bullish sentiment among experts.

STE Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $253.00, with a high forecast of $265.00 and a low forecast of $215.00.
: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STE shares.
: According to analysts, STERIS's stock has a predicted upside of 15.95% based on their 12-month stock forecasts.
: Over the previous 90 days, STERIS's stock had 1 upgrade by analysts.
: STERIS has been rated by research analysts at JMP Securities, Needham & Company LLC, Piper Sandler, and Stephens in the past 90 days.
: Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how STE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

This page (NYSE:STE) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Stock Forecast & Price Target